Table 5.

Design of randomized trials testing metformin as a treatment for abdominal aortic aneurysm

Trial	Registration number	Planned sample size	Design	Daily dose	Control	Primary outcome	Anticipated completion data
MAT134	ACTRN12618001707257	1954 to achieve 616 primary outcome events	PCRT; active 6 week run-in; event driven	1500 mg	Placebo	AAA repair or rupture	2028
MAGGI142	NCT04224051	500	Open label	2000 mg	No metformin	AAA growth measured by orthogonal diameter from CT over 5 years	2026
LIMIT143	NCT04500756	480	PCRT	2000 mg	Placebo	AAA growth measured by orthogonal diameter from CT over 24 months	2028
Met-AAA144	NCT03507413	170	PCRT	2000 mg	Placebo	AAA growth measured by orthogonal diameter from CT over 12 months	2023

MAT, Metformin Aneurysm Trial; MAGGI, Metformin for Abdominal Aortic Aneurysm Growth Inhibition; LIMIT, Limiting Abdominal Aortic Aneurysm With Metformin Trial; PCRT, placebo-controlled randomized trial; CT, computed tomography; Met-AAA, metformin therapy to inhibit progression in non-diabetic patients with abdominal aortic aneurysm.